Cantor Fitzgerald Brokers Boost Earnings Estimates for ZVRA

Zevra Therapeutics, Inc. (NASDAQ:ZVRA) – Equities researchers at Cantor Fitzgerald increased their FY2025 earnings per share estimates for shares of Zevra Therapeutics in a research report issued on Wednesday, May 14th. Cantor Fitzgerald analyst K. Kluska now anticipates that the company will post earnings per share of ($0.17) for the year, up from their prior estimate of ($0.28). Cantor Fitzgerald currently has a “Overweight” rating and a $25.00 price objective on the stock. The consensus estimate for Zevra Therapeutics’ current full-year earnings is ($1.95) per share.

A number of other equities analysts have also recently issued reports on the company. Citigroup reissued an “outperform” rating on shares of Zevra Therapeutics in a report on Wednesday. HC Wainwright reissued a “buy” rating and issued a $20.00 target price on shares of Zevra Therapeutics in a report on Thursday, March 13th. Guggenheim increased their target price on Zevra Therapeutics from $20.00 to $22.00 and gave the stock a “buy” rating in a report on Thursday, March 13th. JMP Securities set a $18.00 target price on Zevra Therapeutics in a report on Wednesday, March 12th. Finally, Canaccord Genuity Group increased their target price on Zevra Therapeutics from $23.00 to $25.00 and gave the stock a “buy” rating in a report on Thursday, March 13th. Eight research analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the company currently has an average rating of “Buy” and an average target price of $22.29.

Zevra Therapeutics Price Performance

Shares of ZVRA stock opened at $8.66 on Friday. The stock has a 50 day moving average of $7.54 and a two-hundred day moving average of $8.07. The company has a current ratio of 2.88, a quick ratio of 2.88 and a debt-to-equity ratio of 0.84. Zevra Therapeutics has a 12 month low of $4.20 and a 12 month high of $9.76. The company has a market capitalization of $473.52 million, a P/E ratio of -4.40 and a beta of 1.87.

Zevra Therapeutics (NASDAQ:ZVRA) last announced its quarterly earnings data on Tuesday, May 13th. The company reported ($0.06) EPS for the quarter, topping analysts’ consensus estimates of ($0.21) by $0.15. Zevra Therapeutics had a negative return on equity of 159.54% and a negative net margin of 342.63%. The company had revenue of $20.40 million during the quarter, compared to the consensus estimate of $16.96 million. During the same quarter last year, the company earned ($0.40) EPS.

Insider Activity at Zevra Therapeutics

In other news, Director John B. Bode bought 10,000 shares of the stock in a transaction dated Wednesday, March 19th. The stock was bought at an average cost of $7.96 per share, with a total value of $79,600.00. Following the purchase, the director now owns 40,000 shares of the company’s stock, valued at approximately $318,400. This represents a 33.33% increase in their ownership of the stock. The purchase was disclosed in a filing with the SEC, which is available at the SEC website. Insiders own 2.40% of the company’s stock.

Institutional Investors Weigh In On Zevra Therapeutics

Hedge funds and other institutional investors have recently made changes to their positions in the company. BNP Paribas Financial Markets acquired a new stake in shares of Zevra Therapeutics in the 4th quarter valued at $53,000. GAMMA Investing LLC increased its stake in shares of Zevra Therapeutics by 20,564.1% in the 1st quarter. GAMMA Investing LLC now owns 8,059 shares of the company’s stock valued at $60,000 after buying an additional 8,020 shares during the period. China Universal Asset Management Co. Ltd. acquired a new stake in shares of Zevra Therapeutics in the 4th quarter valued at $94,000. Squarepoint Ops LLC increased its stake in shares of Zevra Therapeutics by 36.1% in the 4th quarter. Squarepoint Ops LLC now owns 16,534 shares of the company’s stock valued at $138,000 after buying an additional 4,384 shares during the period. Finally, ProShare Advisors LLC acquired a new stake in shares of Zevra Therapeutics in the 4th quarter valued at $145,000. 35.03% of the stock is owned by institutional investors and hedge funds.

About Zevra Therapeutics

Zevra Therapeutics, Inc discovers and develops various proprietary prodrugs to treat serious medical conditions in the United States. The company develops its products through Ligand Activated Therapy platform. Its lead product candidate is KP1077, consisting of KP1077IH, which is under Phase 2 clinical trial for the treatment of idiopathic hypersomnia, and KP1077N, which is under Phase ½ clinical trial to treat narcolepsy.